martinostat
Martinostat is a histone deacetylase inhibitor (HDACi) that is potent against recombinant class I HDACs and class IIb HDAC with low nanomolar affinities. In tissue CETSA assays, martinostat exhibits selectivity for class I HDACs. When tagged with the radioisotope carbon-11, martinostat can be used to quantify HDAC in the brain and peripheral organs using positron emission tomography. Martinostat was given a name that adopted the style of other HDAC inhibitors, such as vorinostat, entinostat, and crebinostat, that recognized the academic center in which it was developed, the Martinos Center for Biomedical Imaging. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2018 (NCT03549559)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histone deacetylase 3INHIBITOR
HDAC3 inhibitor
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
- Histone deacetylase 6INHIBITOR
HDAC6 inhibitor
- Histone deacetylase 1INHIBITOR
HDAC1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMartinostat ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03721211 | Phase 1 | Oct 31, 2018 | Harvard University |
| NCT03549559 | N/A | Jul 1, 2018 | Harvard University |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2018 |